Early-stage drug development is one of the most capital-intensive endeavors in any industry. According to the Tufts Center for the Study of Drug Development, bringing a new drug from discovery through Phase I approval can require anywhere from $200 million to over $1 billion when accounting for the cost of failure across a portfolio. For lean pre-clinical and Phase I companies, every dollar that does not go directly toward science is scrutinized. Yet administrative and operational demands do not shrink simply because a company is small.
Virtual assistants (VAs) with life sciences administrative experience are stepping into this gap — handling the work that consumes scientist and founder hours without delivering proportional scientific value.
The Administrative Burden Holding Back Early-Stage Innovators
Pre-IND and Phase I biotech teams routinely report that senior scientists spend 20 to 30 percent of their working week on tasks that are not bench work: coordinating with CROs, preparing meeting materials for the scientific advisory board, tracking regulatory milestone calendars, organizing literature databases, and managing grant or SBIR correspondence.
The National Institutes of Health reports that SBIR and STTR programs awarded over $4.1 billion to small businesses in fiscal year 2023, with life sciences capturing a dominant share. Managing the reporting, milestone tracking, and reapplication timelines for even a single SBIR award can represent a significant administrative load for a three-to-five person founding team.
A virtual assistant handling that correspondence, deadline tracking, and document preparation frees a scientific lead to focus on experimental design and data review — which is where their value actually compounds.
Key Tasks VAs Handle for Drug Development Startups
Early-stage drug development VAs support a wide range of functions that fall outside pure laboratory work:
Regulatory timeline and document coordination. VAs can maintain master regulatory calendars, track FDA correspondence due dates, compile pre-IND meeting materials, and organize the document repositories that precede an IND filing. While a VA does not draft regulatory strategy, organizing the inputs for that strategy is a legitimate and time-consuming task.
CRO and vendor communication management. Most early-stage companies rely on a network of CROs and analytical labs. Coordinating study quotes, statement-of-work revisions, sample shipment logistics, and data deliverable follow-ups consumes hours that could be redirected. A VA managing vendor inboxes and escalation protocols keeps projects on schedule.
Investor and board communications. Investor update cadences, data room maintenance, board deck assembly, and scheduling investor calls are consistent drains on founder time. VAs with experience in investor relations support can handle the logistics and document prep that keep these relationships professional and current.
Literature monitoring and database hygiene. Competitive intelligence and scientific literature tracking are critical in early-stage development. VAs can run PubMed and patent database searches on defined parameters, organize results into curated digests, and maintain citation databases — giving scientific leads a clean information flow without doing the searching themselves.
Why Hiring Full-Time Staff Is Often Not the Answer
For a company pre-Series A, adding a full-time operations coordinator or executive assistant carries fully-loaded costs of $80,000 to $110,000 annually in most U.S. markets, according to Bureau of Labor Statistics occupational data. Beyond salary, benefits, equity, and office infrastructure compound the cost.
A virtual assistant engagement, by contrast, is typically structured as a monthly retainer for a defined number of hours — no benefits burden, no equity dilution, and scalable up or down as project phases shift. For a company that needs 20 hours of operational support per week during an IND preparation sprint but only 8 hours during a quieter period, the flexibility has direct financial value.
Choosing the Right VA for a Drug Development Context
Not every general VA is suited for drug development support. The most effective candidates have exposure to life sciences terminology, understand basic regulatory vocabulary (IND, CRO, GLP, CMC), and are familiar with the documentation cadence of clinical development. Firms that specialize in placing VAs for healthcare and life sciences clients — like Stealth Agents — provide pre-vetted candidates with relevant domain background, reducing the onboarding friction that would otherwise erode the efficiency gain.
Early-stage drug development companies that treat VA support as a strategic resource — not just a clerical add-on — consistently report faster milestone cadences and meaningfully reduced founder administrative burden.
Sources
- Tufts Center for the Study of Drug Development, "Cost to Develop and Win Marketing Approval for a New Drug" (2020 update)
- National Institutes of Health, "SBIR/STTR Program Funding and Awards, Fiscal Year 2023"
- U.S. Bureau of Labor Statistics, Occupational Employment and Wage Statistics, Administrative and Executive Assistants (2024)